Pfizer (PFE) Non-Current Assets (2009 - 2026)

Pfizer (PFE) has 18 years of Non-Current Assets data on file, last reported at $165.2 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $165.2 billion, up 1.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $651.8 billion (down 6.28% YoY), and the FY2025 annual result was $3.3 billion, up 2.3% from the prior year.
• Non-Current Assets improved to $165.2 billion in Q1 2026 per PFE's latest filing, from $3.3 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $178.7 billion in Q1 2024 and troughed at $3.0 billion in Q4 2023.
• A 5-year average of $113.2 billion and a median of $145.5 billion in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets retreated 15.41% in 2022, then soared 300.49% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $3.0 billion in 2022, then dropped by 0.17% to $3.0 billion in 2023, then climbed by 7.11% to $3.2 billion in 2024, then gained by 2.3% to $3.3 billion in 2025, then soared by 4909.95% to $165.2 billion in 2026.
• Business Quant data shows PFE's Non-Current Assets at $165.2 billion in Q1 2026, $3.3 billion in Q4 2025, and $162.1 billion in Q3 2025.